Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

By Dr Daniel R. Karlin, MD, MA Chief Medical Officer, MindMed

Articles by By Dr Daniel R. Karlin, MD, MA Chief Medical Officer, MindMed

Back to the Future: Psychedelics and a Return to the Concept of Recovery in Psychiatry

ByBy Dr Daniel R. Karlin, MD, MA Chief Medical Officer, MindMed

September 26th 2022

Latest Updated Articles

Back to the Future: Psychedelics and a Return to the Concept of Recovery in Psychiatry
September 26th 2022

Trending on Psychiatric Times

The Postmodern Worldview and Contemporary Psychiatry

New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

Choosing Sexual Function-Sparing Medications

State Funding for Suicide Prevention and Crisis Services Climbs Sharply From 2021 to 2026